Investing

Biotech Implosion: Idenix Pharmaceuticals (IDIX)

Idenix Pharma (NASDAQ:IDIX) this morning announced that its Valopicitabine development program was placed on clinical hold in the United States after discussions with the FDA.  Unfortunately this was the company’s hoped-for hepatitis C treatment.

Jean- Pierre Sommadossi, Ph.D., chairman & CEO of Idenix: "We are disappointed with the FDA’s perspective on the program and are working with Novartis to evaluate our options for valopicitabine.  We remain committed to building a leading antiviral franchise and will continue to focus on ensuring a successful launch of Tyzeka®/Sebivo® and on advancing our pipeline. We have a novel non-nucleoside reverse transcriptase inhibitor being evaluated in phase I clinical testing for the treatment of HIV. Additionally, we have a comprehensive HCV discovery effort, which includes a second-generation nucleoside polymerase inhibitor that is being evaluated in IND-enabling preclinical testing and novel HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs."

The company claims approximately $160 million of cash on hand at June 30 and said it will be reviewing expenses and will review investing in programs it thinks can maximize shareholder value.  As of March 31 it carried $82.646 million in total liabilities, so don’t look at that cash level as "net cash after liabilities."

Shares are down 17% to $4.78 pre-market, down 17% or so from the $5.59 52-week low and down well over 50% from the $11.21 52-week highs.  Its market cap before this drop was $325 million.

Jon C. Ogg
July 13, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Are You Ahead, or Behind on Retirement?

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: am I ahead, or behind on my goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With Zoe Financial’s free matching tool, you can connect with trusted financial advisors in minutes. 

Why wait? Click here to get started today!

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.